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The efficacy of pseudoephedrine (PSE) as a  nasal decongestant has been well‑demonstrated; however, PSE is strictly prescribed 
as a  control substance due to its controversial psychostimulant effects. Although standard stimulatory drugs increase exploratory 
behavior and stimulate the dopamine system, the exact effects of PSE on locomotion and electrical activity in the striatum have 
not been determined. This study aimed to examine and compare the locomotor activities, local field potential (LFP) and sleep‑wake 
patterns produced by PSE and morphine, which is a standard drug used to promote psychomotor activity. Male Swiss albino mice were 
anesthetized and implanted with an intracranial electrode into the striatum. Animals were divided into four groups, which received 
either saline, PSE or morphine. Locomotor activity and LFP signals were continuously monitored following pseudoephedrine or 
morphine treatment. One‑way ANOVA revealed that locomotor count was significantly increased by morphine, but not PSE. Frequency 
analyses of LFP signals using fast Fourier transform also revealed significant increases in spectral powers of low‑ and high‑gamma waves 
following treatment with morphine, but not PSE. Sleep‑wake analysis also confirmed significant increases in waking and decreases in 
both non‑rapid eye movement and rapid eye movement sleep following morphine treatment. Sleep‑wakefulness did not appear to be 
disturbed by PSE treatment. These findings indicate that acute PSE administration, even at high doses, does not have psychostimulatory 
effects and may be relatively safe for the treatment of non‑chronic nasal congestion.
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INTRODUCTION
Pseudoephedrine (PSE) is an effective deconges‑
tant for the treatment of a stuffy nose and has been 
shown to reduce nasal resistance, as a sympathomimet‑
ic drug (Hendeles, 1993). Efficacy for oral PSE against 
nasal congestion during the common cold has been 
consistently demonstrated by several studies (Loose 
and Winkel, 2004; Mizoguchi et al., 2007). However, 
there were warnings that PSE might have health risks 
and that over‑the‑counter sales should be banned re‑
petitive administration of PSE was found to produce 
tolerance similar to that of amphetamine, a standard 
psychostimulant (Ruksee et al., 2008). The risk/benefit 
ratio of PSE use in patients with allergic rhinitis must 
be carefully weighed based on the occurrence of neu‑
rological adverse events (for review see Laccourreye et 
al., 2015). Physicians should be aware of the potential 
for complications, including stroke and neurological 
effects (N’Sondé and Wallaert, 2014).
However, PSE is safe and effective for the treat‑
ment of nasal congestion associated with acute up‑
per respiratory tract infections (Eccles et al., 2005). 
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The efficacy of PSE against nasal congestion, without 
associated side effects, has been reported by a pro‑
spective, randomized, double‑blind trial compared 
with placebo treatment (Eccles et al., 2005). More‑
over, PSE combined with H1 antihistamine was found 
to be effective compared with placebo for four weeks 
(Nathan et al., 2006). In addition, 15‑day treatment 
with oral PSE was more effective against nasal con‑
gestion than treatment with an oral leukotriene re‑
ceptor antagonist (Mucha et al., 2006). However, PSE 
was demonstrated to produce CNS effects resembling 
those produced by amphetamine, with the potential 
to act as a drug of addiction (Tongjaroenbuangam et 
al., 1998). In general, the use of psychostimulants, 
such as amphetamine, methamphetamine, cocaine, 
or cathinone, has been associated with movement 
disorders. Psychostimulants may disrupt movement 
control and produce hypokinetic or hyperkinetic 
disorders, including parkinsonism, tremor, dyskine‑
sias, and myoclonus (for review see Asser and Taba, 
2015). Amphetamine has been used to induce locomo‑
tor activity in an animal model (Schmidt et al., 2010). 
The underlying mechanism of amphetamine involves 
pre‑synaptic release of multiple monoamines, includ‑
ing noradrenaline, dopamine, and serotonin, and the 
inhibition of their reuptake from the synaptic cleft, 
which results in overall CNS activation and enhanced 
alertness (Iversen and Iversen, 1981). In contrast, 
morphine causes somnolence‑like depressive activity 
(Wiffen et al., 2014) but also exhibits locomotor activ‑
ity, as an excitatory effect (Babbini and Davis, 1972), 
indicating that morphine activates relatively direct 
CNS mechanisms, rather than enhancing cortical hy‑
perexcitability or alertness, to increase locomotor 
activity. Moreover, morphine is an opioid that affects 
the electrical activities of the nucleus accumbens and 
striatum and increases movement in mice (Reakkam‑
nuan et al., 2017), indicating that drugs of abuse or 
addiction modulate movement control, either directly 
or indirectly through the activation of the basal gan‑
glia. PSE also increases Fos‑like activity, both in the 
nucleus accumbens and the striatum, which are the 
brain areas that are essential for reinforcing effects 
and locomotor functions, respectively (Kumarnsit et 
al., 1999), indicating that PSE has CNS effects on the 
basal ganglia at the cellular level. Therefore, it is im‑
portant to determine whether PSE acts as a psycho‑
stimulant affecting electrical activity of the striatum 
and increasing locomotor level.
The purpose of the present study was to detect 
changes in local field potential oscillatory patterns 
following PSE treatment in male Swiss ICR mice. Ad‑
ditionally, locomotor activity was monitored to de‑
termine the psychostimulant effects of PSE at the be‑
havioral level. These studies will determine whether 
PSE stimulates the striatum, a psychomotor‑associat‑
ed brain region, and enhances exploratory behaviors. 
Morphine was used as a standard drug. Animals were 
implanted with an intracranial electrode in the stria‑
tum, for LFP signal recording. Animal movement was 
monitored by a web‑based camera. The tested hypoth‑
esis was that a 15 mg/kg morphine dose would clearly 
alter LFP oscillations, whereas PSE (at doses of 50 and 
100 mg/kg oral) would not. 
METHODS
Animal models
Male Swiss albino ICR mice (25–45g) were supplied 
by the Southern Laboratory Animal Facility of Prince 
of Songkla University (Songkhla, Thailand). Animals 
were housed under standard environmental conditions 
(22±2°C, 55±10% humidity, and a 12/12‑h light/dark cy‑
cle), and fed with standard commercial food pellets and 
water, ad libitum. Animals were used repeatedly, to re‑
duce variability among individual animals and across 
different groups, to minimize the numbers of animals 
used and to reduce animal suffering, according to the 
guiding principles underpinning the humane use of 
animals in scientific research, referred to as the Three 
Rs ‑ Replacement, Reduction, Refinement. The exper‑
imental protocols for the care and use of animals that 
are described in the present study were approved and 
guided by the Animal Ethical Committee of the Prince 
of Songkla University, under project license number 
MOE 0521.11/1560 Ref.70/2018.
Intracranial electrode implantation
A surgical procedure was performed for stereo‑
taxic implantation of intracranial electrodes into the 
striatum. Animals were anesthetized, using a mixture 
of xylazine and zoletil, at 15 mg/kg and 50 mg/kg i.p., 
respectively. After animals were deeply anesthetized, 
their head was fixed with a stereotaxic apparatus. 
Stainless‑steel electrodes (279.4 μm in diameter, coat‑
ed) were stereotaxically implanted into the striatum 
(AP: +0.5 mm, ML: 2 mm to bregma, and DV: 3 mm). 
The reference electrode was fixed on the skull, at the 
midline over the cerebellum. All electrodes were se‑
cured in place using dental acrylic (Unifasttrad, Ja‑
pan). A stereotaxic coordinate atlas was used to define 
the flat‑skull positions (Paxinos and Franklin, 2004). 
After surgery, animals were housed individually, in 
single cages, and left for 10 days to recover from sur‑
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gery fully. The antibiotic ampicillin (General Drug 
House Co., Ltd., Thailand) was given intramuscularly, 
once per day, for three consecutive days, to prevent 
infection. At the end of the experiment, the accuracy 
of the electrode implantation was verified using his‑
tology. The animal brains were perfused and fixed in 
paraformaldehyde, embedded in paraffin, and coro‑
nally cut into 10‑mm brain slices. Finally, the location 
of the electrode tip was confirmed within the striatum 
(Fig. 1).
Recording and monitoring LFP patterns and 
locomotor activity
Animals were habituated to the recording condi‑
tions in a chamber for 180 min each day, for three con‑
secutive days. On the experimental day, animals were 
randomly treated with either 0.9% NaCl (p.o), 50 mg/kg 
PSE, 100 mg/kg PSE (p.o), or 15 mg/kg morphine (i.p.) 
and individually placed into the recording cham‑
ber for LFP and locomotor recording (n=9 per group). 
A ball‑tipped, stainless‑steel, gavage pipette was used 
for the intragastric administration of PSE. Post‑drug 
recording was performed for 3 h after drug adminis‑
tration (Fig. 2). Altogether, each animal was given all 
4 treatments, with a 7‑day washout period between 
treatments.
LFP signals were filtered through low‑pass, at 
200 Hz, high‑pass, at 1 Hz, and digitized, at 2 kHz, by 
a PowerLab 16/35 system (AD Instruments, Castle Hill. 
NSW, Australia), with a 16‑bit A/D. Data were stored 
in a PC, through the LabChart 7 software. Notch filter‑
ing, at 50 Hz, was applied to remove noises from power 
line artifacts. All LFP signals were processed through 
a 1–200 Hz band‑pass digital filter (raw filtered signal). 
Fast Fourier transform (FFT) was used to analyze the 
spectral power of 6 discrete frequency bands: delta, 
1–4 Hz; theta, 5–8 Hz; alpha, 9–12 Hz; beta, 13–34 Hz; 
low‑gamma, 35–45 Hz; and high‑gamma, 46–100 Hz. 
The spectral powers of discrete frequency bands un‑
der each treatment condition were averaged and ex‑
pressed, either in time or frequency domains. The loco‑
motor activities of the animals were recorded by using 
a video camera mounted on the top of the recording 
chamber. For the analysis, raw LFP signals and the vid‑
eo of moving animals were continuously transferred to 
a computer for data processing by LabChart software. 
The FFT algorithm was used to perform frequency pow‑
er analyses.
Locomotor counts were analyzed, as described pre‑
viously (Cheaha et al., 2014). A video camera was ver‑
tically mounted over the recording chamber to cap‑
ture the animal images. For the analysis, the images 
of moving animals were continuously transferred to 
a computer for data processing. A tracking system was 
used to analyze the movement details of each animal. 
In brief, the videos in this study were processed pro‑
ficiently by MATLAB software, including Autotyping 
15.04. By using software, the floor space of the record‑
ing chamber was defined as the area that the animal 
could explore. Analyses of animal movements were 
based on the detection of contrasts between the animal 
body (white) and the chamber background (black). The 
animal body was tracked with a red (in the web ver‑
sion) spot. The software was programmed to count the 
Fig.  1. Implantation and histological confirmation of an intracranial 
electrode in the striatum. The wire electrode was stereotaxically 
introduced into the striatum. At the end of the experiment, the mouse 
whole brain was collected, and a coronal brain slice was made through the 
striatum. A mouse brain atlas was used to confirm the electrode location 
within the striatum. 
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number of movements. One count was determined as 
a period of continuous translocation until the animal 
stopped.
Sleep‑wake parameters were analyzed from vid‑
eo records and LFP signals, following each treatment 
(Fig. 3). Video records of individual animals were used 
to identify periods of mobility and immobility. Then, 
LFP signals were converted into spectrograms to visu‑
alize changes in oscillations. Sleep spindles were iden‑
tified by filtering the activity in the 12–16 Hz range. 
Previously, sleep spindles have been found during 
non‑rapid eye movement (NREM) sleep, in both corti‑
cal and subcortical brain regions, including the stria‑
tum (Boutin et al., 2018). Sleep spindles do not appear 
during rapid eye movement (REM) sleep or waking pe‑
riods. The waking brain states were identified by in‑
termittent locomotor activities and the appearance of 
extra gamma activity.
Statistical analysis
All data were averaged and expressed as the mean ± 
standard error of the mean (S.E.M.). The effects of PSE 
Fig. 3. The determination and scoring of sleep‑wake parameters following pseudoephedrine and morphine treatments. Video records of locomotor activity 
and local field potential (LFP) signals were used. Animal movement, LFP sleep spindles, and gamma brain activity were used to determine periods of 
non‑rapid eye movement (NREM) and REM sleep and waking states.
Fig. 2. Experimental procedure for testing the effects of pseudoephedrine and morphine administrations on spontaneous local field potential (LFP) signals 
and locomotor activity. Animals were anesthetized for intracranial electrode implantation, habituated with testing conditions, and repeatedly administered 
different treatments for the recording of LFP raw signals and locomotor activity.
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and morphine administrations on LFP power, frequency, 
and time and locomotor activity levels were analyzed by 
a repeated measure one‑way ANOVA followed by multi‑
ple comparisons using the Student‑Newman‑Keuls post 
hoc test, to indicate specific points of significance. Dif‑
ferences were considered to be significant at p<0.05.
Fig. 4. Monitoring locomotor activity following saline, 50 and 100 mg/kg pseudoephedrine, and 15 mg/kg morphine treatments. A web‑based camera was 
used to record animal movement. The levels of animal movements were detected by a tracking system. Movements within a specific area of the recording 
chamber are represented by grayscale code. 
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RESULTS
Locomotor activity levels following 
pseudoephedrine and morphine treatments
The exploratory movements of animals were mon‑
itored by using a web‑based camera. Patterns of am‑
bulatory behavior were computed by using a tracking 
system (Fig. 4). The movement patterns of 4 represen‑
tative animals, during a 60‑90 min period, are shown. 
The effects of treatments were compared to the levels 
in mice treated with saline control. The results showed 
that morphine increased animal movements, where‑
as PSE did not appear to affect animal movements, at 
either 50 or 100 mg/kg body weight (BW). A one‑way 
ANOVA also confirmed a significant increase in lo‑
comotor counts induced by morphine (F(3,35)=31.350, 
p<0.05) (Fig. 5). No significant difference in locomotor 
counts was observed following PSE treatments.
Local field potential oscillations in the striatum 
following pseudoephedrine and morphine 
treatments
Following morphine or PSE treatments, the raw 
signals of local field potential oscillations were sub‑
jected to visual inspection. Brain waves from rep‑
resentative animals, under the four different treat‑
ment conditions, were compared (Fig. 6). The results 
showed that the brain waves from all animals con‑
tained both slow and fast activities within the raw 
signals. PSE treatment, at both 50 and 100 mg/kg 
BW, appeared to produce similar local field potential 
patterns as saline treatment. In contrast, differential 
signaling patterns were observed following 15 mg/kg 
BW morphine treatment, including additional fast ac‑
tivities, with gamma activity superimposed on basic 
slow‑wave signals.
Raw signals were also expressed as spectrograms 
for inspection of frequency activities in time domain. 
Spectrograms of representative animals that received 
four different treatments were shown (Fig. 7). In com‑
parison with the spectrogram for control animals, 
PSE‑treated animals (both 50 and 100 mg/kg BW) ap‑
peared to show baseline levels of local field potentials. 
Relatively similar activities were observed for fre‑
quencies below 50 Hz. In contrast, dominant gamma 
frequency activity was observed following morphine 
treatment. Gamma activity clearly increased and ebbed 
within 3 h following morphine treatment.
Finally, frequency analyses of local field potentials 
during a 60‑90 min period were focused to reveal the 
spectral powers in the frequency and time domains. Lo‑
cal field potentials were analyzed and expressed as per‑
cent total power every 30 mins (Fig. 8A‑F). The results 
Fig. 5. Effects of morphine and pseudoephedrine treatments on locomotor activity levels. Locomotor counts were averaged and expressed as the mean 
± S.E.M. The effects of treatment were determined using a one‑way ANOVA, followed by multiple comparisons with the Student‑Newman‑Keuls post hoc 
test. n=9. * P≤0.05 compared with the control group.
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showed increases in the frequency ranges for low‑gam‑
ma and high‑gamma bands, starting from 0‑30 min 
until 150‑180 min. Therefore, data from all time peri‑
ods were collected for statistical analyses. Significant 
differences in low‑gamma and high‑gamma powers 
were found during all examined periods, including 
0‑30 min [low‑gamma (F(3,35)=7.487, p<0.05), high‑gam‑
ma (F(3,35)=4.261, p<0.05)], 30‑60 min [low‑gamma 
(F(3,35)=11.662, p<0.05), high‑gamma (F(3,35)=6.262, p<0.05)], 
60‑90 min [low‑gamma (F(3,35)=6.401, p<0.05), high‑gam‑
ma (F(3,35)=11.755, p<0.05)], 90‑120 min [low‑gam‑
ma (F(3,35)= 4.670, p<0.05), high‑gamma (F(3,35)=5.292, 
p<0.05)], 120‑150 min [low‑gamma (F(3,35)=7.979, p<0.05), 
high‑gamma (F(3,35)=10.503, p<0.05)], and 150‑180 min 
[low‑gamma (F(3,35)=5.709, p<0.05), high‑gamma 
(F(3,35)=7.731, p<0.05)] (Fig. 9). Multiple comparisons also 
indicated that significant increases in low‑gamma and 
high‑gamma powers were only produced by morphine 
treatment. Neither the 50 nor 100 mg/kg BW PSE dose 
produced significant differences in power for these fre‑
quency bands. Moreover, the gamma powers of a wide 
frequency range of (35–100 Hz) were analyzed and ex‑
pressed in the time domain. Gamma power was clear‑
ly increased by morphine but not by PSE treatment 
(Fig. 10A). Both the 50 and 100 mg/kg BW PSE treat‑
ment doses produced only baseline levels of gamma ac‑
tivity. Therefore, the averaged gamma powers during 
the 60–180 min period were statistically analyzed 
(Fig. 10B). A one‑way ANOVA revealed that gamma ac‑
tivity was significantly increased only by the morphine 
treatment (F(3,35)=9.975, p<0.05). No significant effects 
on gamma activity were produced by PSE treatments.
Sleep‑wakefulness following pseudoephedrine 
and morphine treatments
The effects of PSE and morphine treatments on 
sleep‑wake patterns were analyzed. Data were scored 
and expressed as the total times of wake, NREM, and REM 
sleep (Fig. 11). One‑way ANOVA revealed significant dif‑
ferences in the wake (F(2,17)=19.263, p<0.05), NREM (F(2,17)= 
16.478, p<0.05), and REM (F(2,17)=7.369, p<0.05) sleep pe‑
riods. Multiple comparisons also indicated that signifi‑
cant increases in the total time spent in all brain states 
were induced by morphine but not PSE.
DISCUSSION
Taken together, the present study clearly demon‑
strated increased locomotor activity and altered local 
field potential oscillations in the striatum of mice in‑
duced by morphine. No changes in these two param‑
eters were observed following treatment with PSE. 
These findings suggest that PSE, even at high doses, is 
not potent enough to act as a stimulant. Movement be‑
havior in animals has been shown to increase following 
Fig. 6. Raw LFP signals in the striatum, following saline, 50 and 100 mg/kg pseudoephedrine, and 15 mg/kg morphine treatments. Representative LFPs of 
4 mice per treatment are displayed in the time‑domain.
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treatment with standard drugs, such as amphetamine 
(McKinzie et al., 2002), cocaine (Yeh and Haertzen, 
1991), modafinil (Simon et al., 1996), ethanol (Kliether‑
mes, 2015), and morphine (Reakkamnuan et al., 2017). 
Enhancement of locomotion appears to be one of the 
most common effects of stimulant drugs. PSE, at a high 
dose (40 mg/kg), was once reported to significantly 
replicate amphetamine effects in rats, according to 
drug discrimination analysis (Tongjaroenbuangam et 
al., 1998). Ideally, drug discrimination analysis is used 
to determine whether a CNS chemical agent alters 
brain functions, leading to changes in mood, feelings, 
perceptions, and/or behaviors similar to those induced 
by a standard psychoactive drug, or results in neutral 
effects, similar to saline. As a sympathomimetic, PSE 
could potentially induce internal changes different 
from those induced by saline. In particular, PSE in‑
creases systolic blood pressure (Hollander‑Rodriguez 
et al., 2017) and causes other neurological effects (Lac‑
courreye et al., 2015), which may be the properties that 
allowed PSE to mimic amphetamine activity. However, 
PSE is unlikely to act as a stimulant, based on the lo‑
comotor activity test and LFP pattern in the striatum. 
These two studies are relatively more direct methods 
that measure stimulant effects in comparison to drug 
discrimination analysis.
Previously, hypokinesia during parkinsonism has 
been reported, following the death of dopaminergic 
neurons in the substantia nigra pars compacta and 
reduced dopamine release in the striatum (Ehringer 
and Hornykiewicz, 1960; 1998), which results in motor 
dysregulation by the striatum. Lesions in the dorsal 
Fig. 7. Representative LFP spectrograms, displaying the dynamics of brain wave frequencies, for saline, 50 and 100 mg/kg pseudoephedrine, and morphine 
treatments. In spectrograms, the values of EEG powers are expressed as a grayscale of frequency against time.
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Fig. 8. Frequency analyses of striatal LFP oscillations. Spectral powers following saline, 50 and 100 mg/kg pseudoephedrine, and morphine treatments 
were analyzed every 30 mins and expressed as a percentage of total power in the frequency domain (A–F). 
Fig.  9. Effects of saline, 50 and 100  mg/kg pseudoephedrine, and 15  mg/kg morphine treatments on low‑ and high‑gamma frequency waves. 
Data are expressed as the mean ± S.E.M. The effects of treatments were determined using a  one‑way ANOVA, followed by multiple comparisons 
(Student‑Newman‑Keuls post hoc test). n=10. * P≤0.05 compared with control levels.
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portion of the anterior striatum increased locomo‑
tor activity, whereas lesions in the ventral striatum 
decreased locomotor activity (Neill et al., 1974). Ad‑
ditionally, the striatum was found to mediate several 
non‑motor functions and is a component of the neural 
circuits associated with the behavioral development of 
drug addiction (Ferguson et al., 2011). Direct and indi‑
rect striatal pathways specifically contribute to asso‑
ciative reward mechanisms and the learning behaviors 
necessary to avoid aversive stimuli, respectively (Hiki‑
da et al., 2010). Increased activity in the direct pathway 
promotes resilience against compulsive cocaine‑seek‑
ing behavior (Bock et al., 2013). These findings sug‑
gested the involvement of the striatum in movement, 
reward, learning and addiction. Differential temporal 
patterns of locomotor activity were also observed fol‑
lowing acute or chronic subcutaneous and intraperi‑
toneal injections of cocaine in rats (Yeh and Haertzen, 
1991). However, cocaine was demonstrated to produce 
both conditioned place preference and increased loco‑
motor activity; however, no significant correlation be‑
tween conditioned place preference, acute locomotor 
activation, and locomotor sensitization was observed 
among multiple mouse strains (Eisener‑Dorman et al., 
2011). These findings indicated that the psychomotor 
and rewarding effects of cocaine are produced by sep‑
arate mechanisms.
Local field potentials induced by standard stimu‑
lants in major brain areas, including the striatum of 
rats, have been analyzed and expressed as electro‑
pharmacograms to predict the efficacy and possible 
mechanisms of action of bioactive substances (Dimp‑
fel, 2009). Changes in the EEG frequency patterns in 
rats were detected in response to the administration 
of multicomponent drugs (Dimpfel et al., 2012). Pre‑
sentation of EEG frequencies following CNS drug ad‑
ministration is sometimes called EEG finger print. In 
human, it has been useful as a quantitative electroen‑
cephalography (qEEG) for investigating the cerebral 
bioavailability of new bioactive compounds (Dimpfel 
et al., 2015). Moreover, striatal activities in response 
to alcohol have been associated with the positive, 
stimulant‑like effects of the drug and the differential 
effects of alcohol among individuals (Weafer et al., 
2018). A consequence of stimulant‑like action was also 
detected in human with attention deficit hyperactivity 
disorder when nicotine consuming reduced primarily 
elevated striatal DAT density (Krause et al., 2002), indi‑
Fig. 10. Time‑course analysis of the effects of 50 and 100 mg/kg pseudoephedrine and 15 mg/kg morphine treatments on gamma oscillations (35–100 Hz) 
in the striatum during a 3 h period. Values were normalized and expressed as a percent of total power (A). The inset values were calculated from the period 
of 60–180 min (B). Data are expressed as the mean ± S.E.M. The effects of treatments were determined by using a one‑way ANOVA, followed by multiple 
comparisons (Student‑Newman‑Keuls post hoc test). n=9. * P≤0.05 compared with control levels.
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cating that the striatum plays a critical role during the 
stimulatory effects of many drugs of addiction.
In terms of mechanism, the striatum appears to 
mediate several actions of psychostimulants. In vivo 
mouse model, (+) amphetamine activates D1 and D2 
dopamine receptors to enhance locomotor activity 
(Simon et al., 1995). Significant decreases in striatal 
dopamine release, DAT availability, and D2/D3 recep‑
tor availability have been reported among stimulant 
users compared with healthy controls (Ashok et al., 
2017). These data suggest that the dopamine system 
in the striatum may be downregulated in stimulant us‑
ers. Apart from stimulation of striatal activity, a major 
character of stimulants is the activation of locomotor 
activity. Ambulation counts were clearly enhanced in 
an animal model, following treatment with 3,4‑methy‑
lenedioxypyrovalerone (MDPV) or methamphetamine 
(Gatch et al., 2013). Previously, standard stimulants, 
such as methamphetamine, MDPV, and mephedrone, 
were found to have both stimulatory and rewarding 
effects following the inhalation of vaporized psycho‑
stimulants (Nguyen et al., 2016). The data may indicate 
a close link between emotionally driven movement 
and reward functions. These findings also suggest that 
the locomotor activity or reinforcement induced by 
stimulant drugs may be health risks associated with 
substances of abuse.
A major concern associated with PSE use is illic‑
it drug production. Several chemical methods have 
been developed to extract and convert PSE into am‑
phetamine (Bogun et al., 2017; Presley et al., 2018). 
Moreover, additional concerns have been raised based 
on research findings showing that PSE acts as a sym‑
pathomimetic. At the level of gene expression, PSE 
has been shown to exhibit stimulatory effects in the 
nucleus accumbens and striatum, two major brain re‑
gions that are generally sensitive to drugs of addic‑
tion (Kumarnsit et al., 1999). PSE produced cross‑tol‑
erance with amphetamine, as measured by c‑Fos pro‑
tein expression, in the brains of chronically treated 
rats (Ruksee et al., 2008). These studies demonstrated 
the CNS effects of i.p. PSE injections, indicating that 
PSE effectively crosses the blood‑brain barrier. How‑
ever, the present study did not show any consistent 
data at the levels of electrical brain and locomotor 
activities, indicating a lack of behavioral phenotype. 
No change of gamma power in the striatum was pro‑
duced by PSE. It means that change in c‑Fos protein 
expression does not lead to the level of LFP activity. 
The influence of immediate early gene expression was 
inadequate to alter gamma oscillation. Previously, an 
i.p. injection of morphine was found to induce gam‑
ma power in the nucleus accumbens, a brain region 
associated with the dopamine pathway (Reakkamnu‑
Fig. 11. Effects of 50 and 100 mg/kg pseudoephedrine and 15 mg/kg morphine treatments on sleep‑wake cycles. The mean time spent in each brain state 
is shown. Sleep‑wake data were analyzed from EEG signals recorded for 3 h following treatment. Data are expressed as the mean ± S.E.M. The effects of 
treatment were determined by using a one‑way ANOVA, followed by multiple comparisons (Student‑Newman‑Keuls post hoc test). n=9. * P≤0.05 compared 
with control levels.
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an et al., 2017), as rapidly as a few minutes following 
injection. Electrical brain activity plays many roles, 
particularly in neural network circuitries. Hence, PSE 
is likely to trigger effects within the striatum, rath‑
er than enhancing neural network connections be‑
tween the striatum and other brain regions through 
gamma oscillations. Moreover, acute treatment with 
PSE did not affect the sleep‑wake pattern, one of the 
most sensitive parameters for examining the effects 
of drugs on the CNS.
CONCLUSION 
Altogether, the present findings demonstrated clear 
evidence of the psychostimulatory effects produced by 
morphine but found no similar effects for PSE. Previous 
studies have reported that cellular activity in the stria‑
tum was induced by PSE treatment. However, the pres‑
ent study confirmed that CNS activities induced by PSE 
have no detectable output at the levels of locomotor 
activity and local field potential oscillations in the stri‑
atum following acute treatment. Further studies might 
be necessary to examine the chronic effects of PSE on 
oscillations in the basal ganglia and locomotion com‑
pared with the levels produced by standard stimulant 
drugs. At this stage, these data support the use of PSE 
for the acute treatment of occasional nasal congestion. 
The continuous use of PSE for chronic diseases, such 
as allergic rhinitis or allergic with asthma, may not be 
recommended. 
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